Xiaolong Zhao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Xiaolong Zhao has a total of 74 co-authors. Here are the top co-authors by number of shared publications:
Chenwei Wu
Department of Endocrinology, Shanghai Public Health Clinical Center, Shanghai, China
7 shared publicationsDuoduo Qu
Department of Endocrinology, Shanghai Public Health Clinical Center, Shanghai, China
6 shared publicationsLihua Zhou
Department of Endocrinology, Shanghai Public Health Clinical Center, Shanghai, China
6 shared publicationsXinyue Xu
Department of Endocrinology, Shanghai Public Health Clinical Center, Shanghai, China
6 shared publicationsChunhong Wang
Department of Endocrinology, Shanghai Public Health Clinical Center, Shanghai, China
5 shared publicationsJia Liu
Department of Endocrinology, Shanghai Public Health Clinical Center, Shanghai, China
5 shared publications
Latest Publications
- Open Access
- 16 February 2026
- Published by Springer Nature in Endocrine
- Vol. 91 (1) , 86
Smart insulin dosage software based on trend arrows: an effective method for controlling hyperglycemia in hospitalized diabetic patients in non-endocrine departments (a randomized controlled trial)
Purpose Artificial intelligence and real-time continuous glucose monitoring (rtCGM) are important inventions in the history of diabetes. The aim of this study was to compare the effectiveness of two methods of glycemic control (smart insulin dosage software and traditional physician’s experience). Methods 86 patients with type 2 diabetes (T2DM) who received multiple daily insulin injections were randomized 1:1 into the smart insulin group (App group) and the traditional physician group (Control group). The former calculates the insulin doses based on an application (which is equipped with trend arrows that reflect the magnitude and direction of glucose changes), while the latter calculates the insulin doses based on physician’s experience. During the study, all participants underwent rtCGM and capillary blood glucose (CBG) testing. The study duration was 5 to 7 days. We compared glucose profile of patients in both group after the intervention. Results Patients in the App group had lower mean CBG (mmol/L) before dinner (10.07 (8.70, 11.60) vs 11.42 (9.89, 14.86), P = 0.006) and at bedtime (9.93 (8.83, 11.33) vs 10.71 (9.62, 12.72), P = 0.039) compared to the control group. The results of rtCGM showed that patients in the App group had lower mean glucose (mmol/L) (9.01(8.04, 9.70) vs10.45 (8.78, 12.27), P = 0.003), higher glucose management index (7.81% (7.09%, 8.59%) vs 7.19%(6.77%, 7.49%), P = 0.003), higher time in range (64.0% (51.0%, 73.0%) vs 47.0% (29.5%, 67.0%), P = 0.001) and less time above of range (35.0% (23.0%, 47.0%) vs 52.0% (29.5.0%, 70.0%), P = 0.003). No significant difference was observed in time below of range (1.0% (0%, 2.0) % vs 0% (0%, 2.5%), P = 0.469). There was no difference in the incidence of hypoglycemia between the two groups of patients (14.0% vs 20.9%, P = 0.394). Conclusion Among T2DM receiving insulin treatment, the smart insulin dosage software with trend arrows has more advantage on controlling hyperglycemia than the physician’s experience. Further research with larger samples and longer durations is needed to support our findings. The clinical trial registration number was NCT05389839.
- 16 February 2026
- Published by Springer Nature in Endocrine
- Vol. 91 (1) , 86
Open AccessSmart insulin dosage software based on trend arrows: an effective method for controlling hyperglycemia in hospitalized diabetic patients in non-endocrine departments (a randomized controlled trial)
Purpose Artificial intelligence and real-time continuous glucose monitoring (rtCGM) are important inventions in the history of diabetes. The aim of this study was to compare the effectiveness of two methods of glycemic control (smart insulin dosage software and traditional physician’s experience). Methods 86 patients with type 2 diabetes (T2DM) who received multiple daily insulin injections were randomized 1:1 into the smart insulin group (App group) and the traditional physician group (Control group). The former calculates the insulin doses based on an application (which is equipped with trend arrows that reflect the magnitude and direction of glucose changes), while the latter calculates the insulin doses based on physician’s experience. During the study, all participants underwent rtCGM and capillary blood glucose (CBG) testing. The study duration was 5 to 7 days. We compared glucose profile of patients in both group after the intervention. Results Patients in the App group had lower mean CBG (mmol/L) before dinner (10.07 (8.70, 11.60) vs 11.42 (9.89, 14.86), P = 0.006) and at bedtime (9.93 (8.83, 11.33) vs 10.71 (9.62, 12.72), P = 0.039) compared to the control group. The results of rtCGM showed that patients in the App group had lower mean glucose (mmol/L) (9.01(8.04, 9.70) vs10.45 (8.78, 12.27), P = 0.003), higher glucose management index (7.81% (7.09%, 8.59%) vs 7.19%(6.77%, 7.49%), P = 0.003), higher time in range (64.0% (51.0%, 73.0%) vs 47.0% (29.5%, 67.0%), P = 0.001) and less time above of range (35.0% (23.0%, 47.0%) vs 52.0% (29.5.0%, 70.0%), P = 0.003). No significant difference was observed in time below of range (1.0% (0%, 2.0) % vs 0% (0%, 2.5%), P = 0.469). There was no difference in the incidence of hypoglycemia between the two groups of patients (14.0% vs 20.9%, P = 0.394). Conclusion Among T2DM receiving insulin treatment, the smart insulin dosage software with trend arrows has more advantage on controlling hyperglycemia than the physician’s experience. Further research with larger samples and longer durations is needed to support our findings. The clinical trial registration number was NCT05389839.
- Open Access
- 27 June 2025
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 16, 1504326
Hypocalcemia is associated with adverse outcomes in patients with diabetes and COVID-19
Background: Patients with diabetes and COVID-19 have a worse prognosis. The aim of this study was to investigate the prevalence of hypocalcemia in patients with diabetes and COVID-19, and assess the relationship between serum calcium levels and prognosis in these patients.Methods: A retrospective analysis was conducted on 919 patients with diabetes admitted for COVID-19 from February 2022 to May 2022. The population was categorized into three groups according to serum calcium levels. The primary outcome was the risk of developing severe COVID-19, and the secondary outcomes included the risk of requiring advanced respiratory support (including high-flow oxygen, non-invasive ventilation, and invasive ventilation). Logistic regression analysis was used to evaluate the association between hypocalcemia and the prognosis of COVID-19 patients with diabetes.Result: Among the 919 patients with diabetes, the median age was 70 (56-81) years, and 498 (54.2%) were male. The prevalence of hypocalcemia in COVID-19 patients with diabetes was 78.8%. The serum calcium level was negatively correlated with inflammatory markers (hsCRP, ESR, PCT, IFN). The serum calcium level was positively correlated with albumin, CD4+ T cell counts, and CD8+ T cell counts. In Multivariate analysis, after adjustment for age and gender, the higher risk of severe illness was observed in patients with a serum calcium level <1.94 mmol/L (OR 2.86, 95%CI [1.78-4.59], P<0.001).Conclusion: Admission serum calcium level is associated with the prognosis of COVID-19 patients with diabetes. Hypocalcemia increases the risk of progression to severe COVID-19 in patients with diabetes.
- 27 June 2025
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 16, 1504326
Open AccessHypocalcemia is associated with adverse outcomes in patients with diabetes and COVID-19
Background: Patients with diabetes and COVID-19 have a worse prognosis. The aim of this study was to investigate the prevalence of hypocalcemia in patients with diabetes and COVID-19, and assess the relationship between serum calcium levels and prognosis in these patients.Methods: A retrospective analysis was conducted on 919 patients with diabetes admitted for COVID-19 from February 2022 to May 2022. The population was categorized into three groups according to serum calcium levels. The primary outcome was the risk of developing severe COVID-19, and the secondary outcomes included the risk of requiring advanced respiratory support (including high-flow oxygen, non-invasive ventilation, and invasive ventilation). Logistic regression analysis was used to evaluate the association between hypocalcemia and the prognosis of COVID-19 patients with diabetes.Result: Among the 919 patients with diabetes, the median age was 70 (56-81) years, and 498 (54.2%) were male. The prevalence of hypocalcemia in COVID-19 patients with diabetes was 78.8%. The serum calcium level was negatively correlated with inflammatory markers (hsCRP, ESR, PCT, IFN). The serum calcium level was positively correlated with albumin, CD4+ T cell counts, and CD8+ T cell counts. In Multivariate analysis, after adjustment for age and gender, the higher risk of severe illness was observed in patients with a serum calcium level <1.94 mmol/L (OR 2.86, 95%CI [1.78-4.59], P<0.001).Conclusion: Admission serum calcium level is associated with the prognosis of COVID-19 patients with diabetes. Hypocalcemia increases the risk of progression to severe COVID-19 in patients with diabetes.
- Open Access
- 23 April 2025
- Published by Wolters Kluwer Health in Chinese Medical Journal
- Vol. 138 (10) , 1257-1259
Severe COVID-19 and inactivated vaccine in diabetic patients with SARS-CoV-2 infection
- 23 April 2025
- Published by Wolters Kluwer Health in Chinese Medical Journal
- Vol. 138 (10) , 1257-1259
Open AccessSevere COVID-19 and inactivated vaccine in diabetic patients with SARS-CoV-2 infection
- Open Access
- 25 September 2024
- Published by Springer Nature in Endocrine
- Vol. 87 (2) , 474-480
Correlation between insulin-like growth factor and complexity of glucose time series index in patients with newly diagnosed acromegaly: a PILOT study
Background Acromegaly has a high risk of abnormal glucose metabolism. The complexity of the glucose time series index (CGI) is calculated from refined composite multi-scale entropy analysis of the continuous glucose monitoring (CGM) data. CGI is a new indicator of glucose imbalance based on ambulatory glucose monitoring technology, which allows for earlier response to glucose metabolism imbalance and correlates with patient prognosis. Objective To compare the differences in glucose metabolic profile and CGI between acromegaly with normal glucose tolerance (NGT) and healthy subjects. Methods Eight newly diagnosed patients with acromegaly (GH group) and eight age- and gender-matched healthy subjects (Control group) were included in this study. All participants underwent oral glucose tolerance test (OGTT) and 72-h CGM. A refined composite multi-scale entropy analysis was performed on the CGM data to calculate the CGI and we compare the differences in glycemic profiles and CGI between the two groups. Results After OGTT, compared with the control group, patients in the GH group had higher 2 h blood glucose (BG) (mmol/L) [GH vs control, 6.7 (6.1, 7.0) vs 5.2 (3.8, 6.3), P = 0.012], 3 h BG [5.1 (3.8, 6.5) vs 4.0 (3.4, 4.2), P = 0.046], mean BG [6.3 (6.1, 6.5) vs 5.5 (5.1, 5.9), P = 0.002], 2 h insulin (mU/L) [112.9 (46.8, 175.5) vs 34.1 (17.1, 55.6), P = 0.009], and 3 h insulin [26.8 (17.1, 55.4) vs 10.4 (4.2, 17.8), P = 0.016]. CGI was lower in the GH group [2.77 (1.92, 3.15) vs 4.2 (3.3, 4.8), P = 0.008]. Spearman’s correlation analysis showed insulin-like growth factor (IGF) (r = −0.897, P < 0.001) and mean glucose (r = −0.717, P = 0.003) were significantly negatively correlated with CGI. Multiple linear stepwise regression showed that IGF-1 (r = −0.652, P = 0.028) was independent factor associated with CGI in acromegaly. Conclusion IGF-1 was significantly associated with CGI, and CGI may serve as a novel marker to evaluate glucose homeostasis in acromegaly with normal glucose tolerance.
- 25 September 2024
- Published by Springer Nature in Endocrine
- Vol. 87 (2) , 474-480
Open AccessCorrelation between insulin-like growth factor and complexity of glucose time series index in patients with newly diagnosed acromegaly: a PILOT study
Background Acromegaly has a high risk of abnormal glucose metabolism. The complexity of the glucose time series index (CGI) is calculated from refined composite multi-scale entropy analysis of the continuous glucose monitoring (CGM) data. CGI is a new indicator of glucose imbalance based on ambulatory glucose monitoring technology, which allows for earlier response to glucose metabolism imbalance and correlates with patient prognosis. Objective To compare the differences in glucose metabolic profile and CGI between acromegaly with normal glucose tolerance (NGT) and healthy subjects. Methods Eight newly diagnosed patients with acromegaly (GH group) and eight age- and gender-matched healthy subjects (Control group) were included in this study. All participants underwent oral glucose tolerance test (OGTT) and 72-h CGM. A refined composite multi-scale entropy analysis was performed on the CGM data to calculate the CGI and we compare the differences in glycemic profiles and CGI between the two groups. Results After OGTT, compared with the control group, patients in the GH group had higher 2 h blood glucose (BG) (mmol/L) [GH vs control, 6.7 (6.1, 7.0) vs 5.2 (3.8, 6.3), P = 0.012], 3 h BG [5.1 (3.8, 6.5) vs 4.0 (3.4, 4.2), P = 0.046], mean BG [6.3 (6.1, 6.5) vs 5.5 (5.1, 5.9), P = 0.002], 2 h insulin (mU/L) [112.9 (46.8, 175.5) vs 34.1 (17.1, 55.6), P = 0.009], and 3 h insulin [26.8 (17.1, 55.4) vs 10.4 (4.2, 17.8), P = 0.016]. CGI was lower in the GH group [2.77 (1.92, 3.15) vs 4.2 (3.3, 4.8), P = 0.008]. Spearman’s correlation analysis showed insulin-like growth factor (IGF) (r = −0.897, P < 0.001) and mean glucose (r = −0.717, P = 0.003) were significantly negatively correlated with CGI. Multiple linear stepwise regression showed that IGF-1 (r = −0.652, P = 0.028) was independent factor associated with CGI in acromegaly. Conclusion IGF-1 was significantly associated with CGI, and CGI may serve as a novel marker to evaluate glucose homeostasis in acromegaly with normal glucose tolerance.
- Open Access
- 24 September 2024
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 15, 1361479
Association between thyroid function and prognosis of severe COVID-19 among patients with SARS-CoV-2 infection: a retrospective cohort study in China
Objective: This study aims to examine the thyroid hormone profile and its association with severe coronavirus disease 2019 (COVID-19) in patients infected by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).Methods: This retrospective cohort study enrolled patients admitted to a tertiary hospital due to SARS-CoV-2 infection between February 18 and May 18, 2022. Clinical data were collected retrospectively from the electronic medical record system. Based on the thyroid function, patients were divided into five groups: normal, non-thyroid illness syndrome (NTIS), hypothyroidism, thyrotoxicosis, and unclassified. The association between thyroid function and severe COVID-19 was detected using multivariable logistic regression and restricted cubic splines analysis.Results: This study included 3,161 patients, with 7.7% of them developing severe COVID-19. 44.9% of the patients had normal thyroid function, 36.5% had NTIS, 6.7% had hypothyroidism, and 1.0% had thyrotoxicosis on admission. After adjusting for age, sex, and relevant clinical characteristics, NTIS and hypothyroidism were associated with increased risks of severe COVID-19 (odds ratio [OR] 2.38, 95% confidence interval [CI] 1.59-3.56 and OR 2.29, 95% CI 1.23-4.26, respectively), compared to normal thyroid function group. Among patients with NTIS or hypothyroidism, higher levels of total triiodothyronine (TT3) are associated with lower risks of severe COVID-19 (OR 0.73, 95% CI 0.64-0.82, for every 0.1nmol/L increase in TT3 level).Conclusion: Thyroid hormone profiles of NTIS or hypothyroidism are associated with increased risks of severe COVID-19. The decreased level of TT3 correlated with the increased risk of severe COVID-19 in patients with NTIS or hypothyroidism.
- 24 September 2024
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 15, 1361479
Open AccessAssociation between thyroid function and prognosis of severe COVID-19 among patients with SARS-CoV-2 infection: a retrospective cohort study in China
Objective: This study aims to examine the thyroid hormone profile and its association with severe coronavirus disease 2019 (COVID-19) in patients infected by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).Methods: This retrospective cohort study enrolled patients admitted to a tertiary hospital due to SARS-CoV-2 infection between February 18 and May 18, 2022. Clinical data were collected retrospectively from the electronic medical record system. Based on the thyroid function, patients were divided into five groups: normal, non-thyroid illness syndrome (NTIS), hypothyroidism, thyrotoxicosis, and unclassified. The association between thyroid function and severe COVID-19 was detected using multivariable logistic regression and restricted cubic splines analysis.Results: This study included 3,161 patients, with 7.7% of them developing severe COVID-19. 44.9% of the patients had normal thyroid function, 36.5% had NTIS, 6.7% had hypothyroidism, and 1.0% had thyrotoxicosis on admission. After adjusting for age, sex, and relevant clinical characteristics, NTIS and hypothyroidism were associated with increased risks of severe COVID-19 (odds ratio [OR] 2.38, 95% confidence interval [CI] 1.59-3.56 and OR 2.29, 95% CI 1.23-4.26, respectively), compared to normal thyroid function group. Among patients with NTIS or hypothyroidism, higher levels of total triiodothyronine (TT3) are associated with lower risks of severe COVID-19 (OR 0.73, 95% CI 0.64-0.82, for every 0.1nmol/L increase in TT3 level).Conclusion: Thyroid hormone profiles of NTIS or hypothyroidism are associated with increased risks of severe COVID-19. The decreased level of TT3 correlated with the increased risk of severe COVID-19 in patients with NTIS or hypothyroidism.
- Open Access
- 29 November 2023
- Published by Wiley in Journal of Diabetes Investigation
- Vol. 15 (1) , 44-51
Association of serum amyloid A and prognosis in people with diabetes and COVID‐19: A retrospective cohort study
Aims/Introduction: Serum amyloid A (SAA) is an acute phase reactive protein that plays a vital role in the early diagnosis, risk prediction, efficacy observation and prognosis evaluation of infectious diseases. This study aimed to assess the association between SAA levels and the prognosis of patients with coronavirus disease 2019 (COVID‐19) and diabetes.Materials and Methods: We carried out this retrospective cohort study from March 2022 to May 2022. The population was stratified by tertiles of SAA levels: low (36 mg/L). The primary outcome was whether the patient developed severe COVID‐19, and secondary outcomes included the need for invasive mechanical ventilation and length of hospital stay. Logistic regression analyses were carried out to identify risk factors affecting the prognosis of patients with COVID‐19 and diabetes.Results: We analyzed 910 diabetes patients with COVID‐19. The median age of the patients was 69 years, and 52.3% were men. As SAA levels increased, the proportion of severe COVID‐19 (6.3% vs 7.3% vs 22.8%, P < 0.001) and the proportion of invasive mechanical ventilation also increased among the three groups. Patients with high SAA levels had a longer length of hospital stay compared with patients with medium SAA and low SAA levels. Univariate logistic regression analysis showed that SAA >36 mg/L further increased the odds ratio to 4.423 (P < 0.001) for the development of severe COVID‐19 compared with low SAA. Multivariate logistic regression analysis, adjusted for age and sex, confirmed that SAA >36 mg/L remained an independent risk factor for the development of severe COVID‐19 (adjusted odds ratio 3.038, P < 0.001).Conclusions: SAA levels are strongly associated with poor prognosis in patients with COVID‐19 and diabetes.
- 29 November 2023
- Published by Wiley in Journal of Diabetes Investigation
- Vol. 15 (1) , 44-51
Open AccessAssociation of serum amyloid A and prognosis in people with diabetes and COVID‐19: A retrospective cohort study
Aims/Introduction: Serum amyloid A (SAA) is an acute phase reactive protein that plays a vital role in the early diagnosis, risk prediction, efficacy observation and prognosis evaluation of infectious diseases. This study aimed to assess the association between SAA levels and the prognosis of patients with coronavirus disease 2019 (COVID‐19) and diabetes.Materials and Methods: We carried out this retrospective cohort study from March 2022 to May 2022. The population was stratified by tertiles of SAA levels: low (36 mg/L). The primary outcome was whether the patient developed severe COVID‐19, and secondary outcomes included the need for invasive mechanical ventilation and length of hospital stay. Logistic regression analyses were carried out to identify risk factors affecting the prognosis of patients with COVID‐19 and diabetes.Results: We analyzed 910 diabetes patients with COVID‐19. The median age of the patients was 69 years, and 52.3% were men. As SAA levels increased, the proportion of severe COVID‐19 (6.3% vs 7.3% vs 22.8%, P < 0.001) and the proportion of invasive mechanical ventilation also increased among the three groups. Patients with high SAA levels had a longer length of hospital stay compared with patients with medium SAA and low SAA levels. Univariate logistic regression analysis showed that SAA >36 mg/L further increased the odds ratio to 4.423 (P < 0.001) for the development of severe COVID‐19 compared with low SAA. Multivariate logistic regression analysis, adjusted for age and sex, confirmed that SAA >36 mg/L remained an independent risk factor for the development of severe COVID‐19 (adjusted odds ratio 3.038, P < 0.001).Conclusions: SAA levels are strongly associated with poor prognosis in patients with COVID‐19 and diabetes.
- 1 June 2023
- Published by Science China Press., Co. Ltd. in Chinese Science Bulletin
- Vol. 68 (19) , 2421-2423
Focus on a special tool for postprandial glucose control: Ultra rapid lispro
- 1 June 2023
- Published by Science China Press., Co. Ltd. in Chinese Science Bulletin
- Vol. 68 (19) , 2421-2423
Focus on a special tool for postprandial glucose control: Ultra rapid lispro
- Open Access
- 20 June 2022
- Published by Taylor & Francis in Blood Pressure
- Vol. 31 (1) , 139-145
Liddle syndrome misdiagnosed as primary aldosteronism is caused by inaccurate aldosterone-rennin detection while a novel SCNN1G mutation is discovered
Through describing the confusing misdiagnosis process of Liddle syndrome, we try to reveal the importance of accurate aldosterone-renin detection and a genetic test for Liddle syndrome.We found a f...
- 20 June 2022
- Published by Taylor & Francis in Blood Pressure
- Vol. 31 (1) , 139-145
Open AccessLiddle syndrome misdiagnosed as primary aldosteronism is caused by inaccurate aldosterone-rennin detection while a novel SCNN1G mutation is discovered
Through describing the confusing misdiagnosis process of Liddle syndrome, we try to reveal the importance of accurate aldosterone-renin detection and a genetic test for Liddle syndrome.We found a f...
- Open Access
- 27 January 2022
- Published by Wolters Kluwer Health in Chinese Medical Journal
- Vol. 135 (21) , 2611-2613
A patient with glucocorticoid hypersensitivity syndrome
An abstract is unavailable. This article is available as a PDF only.
- 27 January 2022
- Published by Wolters Kluwer Health in Chinese Medical Journal
- Vol. 135 (21) , 2611-2613
Open AccessA patient with glucocorticoid hypersensitivity syndrome
An abstract is unavailable. This article is available as a PDF only.
- Open Access
- 7 December 2021
- Published by Wiley in International Journal of Endocrinology
- Vol. 2021, 1-7
The Beta-Cell Function and Glucose Profile of Newly Diagnosed Acromegalic Patients with Normal Glucose Tolerance
Objectives. Untreated acromegaly is a nature model for unveiling the diabetogenic effects of GH. CGMS can uncover more glucose profile of acromegaly. This study aimed to evaluate the insulin resistance (IR), β-cell function, and glycemic spectrum of patients with newly diagnosed acromegaly with normal glucose tolerance (NGT). Methods. This study was conducted in Huashan Hospital from January 2015 to February 2019. Eight newly diagnosed acromegalic patients without history of diabetes and eight age- and gender-matched healthy subjects were enrolled. All participants underwent oral glucose tolerance test (OGTT) and 72h continuous glucose monitoring (CGM). Parameters on β-cell function and IR were calculated. Mean blood glucose (MBG) in 24 hours was adopted for the evaluation of the glycemic level, and standard deviation of blood glucose (SDBG) and mean amplitude of glycemic excursion (MAGE) were used for glucose fluctuation. Results. HbA1c in the acromegaly group was significantly higher than in the control. During OGTT, glucose peaked at 60min in acromegaly and at 30min in controls. After glucose load, the acromegaly group had significantly higher insulin levels than controls, especially in 120min and 180min. Both insulin sensitivity index and disposal index after glucose load of acromegaly were significantly lower than those of controls. Moreover, acromegalic subjects had significantly higher MBG than controls. Conclusions. The newly diagnosed acromegalic patients with NGT were characterized by IR and impaired β-cell function after glucose load. CGM showed that MBG of NGT acromegaly patients was higher than that of normal people.
- 7 December 2021
- Published by Wiley in International Journal of Endocrinology
- Vol. 2021, 1-7
Open AccessThe Beta-Cell Function and Glucose Profile of Newly Diagnosed Acromegalic Patients with Normal Glucose Tolerance
Objectives. Untreated acromegaly is a nature model for unveiling the diabetogenic effects of GH. CGMS can uncover more glucose profile of acromegaly. This study aimed to evaluate the insulin resistance (IR), β-cell function, and glycemic spectrum of patients with newly diagnosed acromegaly with normal glucose tolerance (NGT). Methods. This study was conducted in Huashan Hospital from January 2015 to February 2019. Eight newly diagnosed acromegalic patients without history of diabetes and eight age- and gender-matched healthy subjects were enrolled. All participants underwent oral glucose tolerance test (OGTT) and 72h continuous glucose monitoring (CGM). Parameters on β-cell function and IR were calculated. Mean blood glucose (MBG) in 24 hours was adopted for the evaluation of the glycemic level, and standard deviation of blood glucose (SDBG) and mean amplitude of glycemic excursion (MAGE) were used for glucose fluctuation. Results. HbA1c in the acromegaly group was significantly higher than in the control. During OGTT, glucose peaked at 60min in acromegaly and at 30min in controls. After glucose load, the acromegaly group had significantly higher insulin levels than controls, especially in 120min and 180min. Both insulin sensitivity index and disposal index after glucose load of acromegaly were significantly lower than those of controls. Moreover, acromegalic subjects had significantly higher MBG than controls. Conclusions. The newly diagnosed acromegalic patients with NGT were characterized by IR and impaired β-cell function after glucose load. CGM showed that MBG of NGT acromegaly patients was higher than that of normal people.